Levtid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levtid

Quick Facts

Property Description
Active Ingredient Levofloxacin
Pharmacological Class Antibiotic (Third-generation Fluoroquinolone)
Origin / Type Synthetic L-isomer of Ofloxacin
Dosage Forms Tablet, oral solution, intravenous solution, ophthalmic solution
General Purpose Bacterial elimination (Bactericidal Action)

What Type of Medicine is Levtid?

Levtid is a prescription-only pharmaceutical product whose identity is fundamentally anchored by its active ingredient, Levofloxacin. Levofloxacin is a potent, synthetic compound classified as an antibiotic and anti-infective agent. It belongs to the Fluoroquinolone class of antibacterials and is a third-generation agent, chemically defined as the purified, active L-isomer of Ofloxacin. This classification and structure provide the basis for its broad-spectrum action.

Levofloxacin: Composition and Available Forms

Levtid is structured as a single-ingredient product, comprising only Levofloxacin and necessary pharmaceutical base/vehicle components. As a single-ingredient product, its effects are solely attributable to the active compound. The medicine is supplied in multiple high-level dosage forms corresponding to various routes of administration, including a solid tablet and a liquid oral solution for systemic use, a sterile intravenous solution for infusion, and an ophthalmic solution for targeted local delivery. These preparations comprise the active substance and bases such as solid excipients or an aqueous solution.

What is the General Purpose of Levtid?

The overarching purpose of Levtid is to achieve a powerful bactericidal action to effectively eliminate harmful bacterial proliferation within the body. Its core function is to cause the definitive cell death of susceptible microorganisms by disrupting their essential DNA maintenance machinery. This highly specific action underscores its utility as an advanced microbial agent for resolving systemic and local issues driven by these bacteria, ensuring a decisive reduction in the population of the targeted organisms.

Regulatory References

  1. NIH StatPearls page on Levofloxacin
  2. WHO Essential Medicines List for Levofloxacin

What side effects are possible with Levtid?

Possible Side Effects and Safety Information

The safety profile of Levofloxacin (the active ingredient in Levtid) is formally structured in regulatory documents, outlining the potential spectrum of adverse reactions and safety limitations. Side effects are classified by how often they may occur, according to regulatory standards (e.g., EMA/FDA).

Common reactions, meaning they are reported in 1% to 10% of patients in studies, often involve the gastrointestinal and nervous systems and include nausea, diarrhea, headache, insomnia, and dizziness. Uncommon and Rare reactions affect fewer patients and are grouped by System-Organ Class (SOC) in official labeling, covering categories like Psychiatric disorders and Blood and lymphatic system disorders.

Serious adverse reactions are specifically highlighted in official documents due to their potential to be disabling or life-threatening. These include tendon rupture (often involving the Achilles tendon), which may occur rapidly or months after stopping treatment, and peripheral neuropathy (nerve damage) that can be irreversible. Other serious effects include QT interval prolongation (a heart rhythm risk) and severe, sometimes fatal, reactions such as Clostridium difficile-associated diarrhea (CDAD) or aortic aneurysm and dissection.

Regulatory documents include safety considerations for specific patient populations. Older adults have an increased risk of tendon effects and QT prolongation. Diabetic patients should be aware of the risk of dysglycemia (both hypoglycemia and hyperglycemia). Use is generally contraindicated in patients with a history of quinolone-associated tendinitis or pre-existing conditions that predispose to seizures.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation details the specific manifestations of Levtid (levofloxacin) overdose, which primarily affect the Central Nervous System (CNS) and Cardiovascular system. In the event of a suspected overdose, immediate medical attention must be sought.


Documented Overdose Manifestations

System Official Regulatory Statement
CNS Signs include confusion, tremors, convulsions (seizures), dizziness, psychotic reactions, and hallucinations.
Cardiovascular The main risk is QT Interval Prolongation, which may lead to the life-threatening ventricular arrhythmia Torsade de Pointes.

Required Emergency Actions and Management

In a suspected overdose or the presentation of severe symptoms, patients must discontinue Levtid immediately. Emergency help-seeking is required when any serious CNS effects or cardiac risks are observed.

Management is strictly symptomatic and supportive. The official labeling mandates continuous ECG monitoring due to the risk of severe cardiac events. For acute oral overdose, gastric lavage may be considered for the removal of unabsorbed drug.

It is officially documented that no specific antidote is known for levofloxacin overdose, and procedures like hemodialysis or peritoneal dialysis are not effective for drug removal. Special caution is noted for diabetic patients due to the risk of profound hypoglycemia leading to coma.

Therapeutic Uses of Levtid

What Levtid Treats: Main Uses and Benefits

Levtid is commonly used across conditions presenting with acute episodes and systemic discomfort, applicable within clinical settings that involve acute or disruptive symptom patterns, such as certain bacterial manifestations in the respiratory tract (e.g., pneumonia and acute exacerbations of chronic bronchitis). The medication is also applied across domains where additional symptomatic support is needed, relevant to conditions marked by increased physiological stress in the urinary tract (pyelonephritis), the prostate, and conditions where symptoms may intensify temporarily in the skin and soft tissues (like cellulitis). It is also relevant in contexts involving heightened systemic burden for managing exposure to specialized high-risk pathogens, including Inhalational Anthrax and Plague.

“Its application contributes to improved comfort during periods of heightened symptoms.” The primary benefit is in addressing symptom clusters that may become intense or disruptive, such as symptoms related to systemic imbalance (fever) and localized inflammation, which create noticeable functional strain. In these acute scenarios, it provides support that helps ease the overall symptom burden and may assist with short-term symptom stabilization.

Quick Fact: Relief for Key Symptom Domains
Symptom Focus Fever, localized pain, inflammation, and discomfort associated with complicated bacterial infections.
Contextual Use Applied during acute episodes characterized by periods of heightened symptoms in respiratory, urogenital, or skin contexts.
Patient Benefit Supports the patient by contributing to improved comfort and assisting with maintaining functional stability during symptomatic phases.

Regulatory References

  1. NIH DailyMed label

Eligibility and Restrictions for Use

The eligibility for using Levtid (Levofloxacin) is strictly determined by official regulatory documents based on a patient's medical history, age, and physiological status.

Populations Who Must Not Use Levtid (Contraindications)

Levtid is formally contraindicated and must not be used by:

  • Patients with known hypersensitivity to levofloxacin, other quinolone antibacterials, or any excipients.
  • Individuals with a history of epilepsy or tendon disorders related to previous fluoroquinolone use.
  • Children and growing adolescents for general systemic use.
  • Pregnant women and breast-feeding women.

Age- and Condition-Based Restrictions

Eligibility is restricted or conditional for certain groups:

Population Group Eligibility Rule (Official Status)
Children/Adolescents Contraindicated for general systemic use; only permitted for specific, high-risk indications (e.g., Anthrax, Plague) in patients ge 6 months old [FDA Label].
Older Adults Use is permitted, but caution is advised due to increased risk of tendon disorders and potential for QT interval prolongation.
Renal Impairment Use is allowed, but requires mandatory dose adjustment based on reduced kidney function.
Comorbidities Use should be avoided in patients with a history of Myasthenia Gravis. Caution is required in patients with diabetes mellitus or risk factors for QT interval prolongation.

Patients receiving corticosteroids or who have had a solid organ transplant are restricted to use with caution due to an increased risk of tendon damage.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Levofloxacin (the active ingredient in Levtid) are officially documented in two primary regulatory domains: those affecting drug exposure and those increasing specific physiological risks.

Pharmacokinetic and Timing-Based Interactions

Interaction Type Interacting Substances Regulatory Restriction
Absorption Interference Multivalent Cations (Antacids containing magnesium or aluminum, Sucralfate, Iron/Zinc supplements, Buffered Didanosine) Oral Levofloxacin must be separated by at least 2 hours before or 2 hours after administration of these products to prevent a significant reduction in drug plasma concentration.
Clearance Reduction Probenecid, Cimetidine These agents inhibit renal tubular secretion, causing a decrease in Levofloxacin clearance and an increase in systemic exposure.

Pharmacodynamic Interactions

Interaction Type Interacting Substances Official Outcome
Additive Risk (Cardiac) QT-Prolonging Agents (e.g., Class IA/III Antiarrhythmics, Macrolides, Antipsychotics) Co-administration carries an additive risk of QT interval prolongation and ventricular arrhythmia.
Additive Risk (Tissue) Corticosteroids Increases the risk of tendinopathy and tendon rupture.
Enhanced Effect Warfarin (Vitamin K Antagonists) Associated with an increased risk of bleeding due to enhanced anticoagulant activity.
Metabolic Disturbance Insulin or Oral Hypoglycemic Agents May cause disturbances in blood glucose levels, including both hypoglycemia and hyperglycemia.

Regulatory documentation notes that food intake does not significantly affect the absorption of Levofloxacin.

Mechanism of Action

Targeting Microbial Genetic Maintenance

Levofloxacin's action is defined by its specific binding and stabilization of the transient complexes formed by two essential bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. These enzymes are essential for managing the replication, structural integrity, and separation of the bacterial genome. The drug inhibits these enzymes, trapping them and preventing them from re-ligating (rejoining) the bacterial DNA strands after they have been cut. This mechanism is focused on the core genetic machinery, which contrasts with mechanisms that primarily disrupt extracellular structures (like cell walls) or cytoplasmic protein production.


Causal Sequence Leading to Pathogen Elimination

The molecular inhibition rapidly initiates a cascading sequence of events. The failure to repair the accumulating DNA damage and the inability to properly segregate replicated chromosomes triggers a critical emergency response within the cell, leading to complete shutdown of essential life functions. This irreversible genetic damage forces the microbial cells into a state of physiological collapse, resulting in the termination of microbial replication and functional clearance of the organisms. The resulting physiological effect is the reduction of the pathogenic load, which is the functional consequence of the bactericidal mechanism.


️ Biological Constraints on Mechanism Efficacy

The drug's mechanism is physiologically constrained by bacterial resistance strategies, primarily involving structural mutation of the target enzymes (DNA Gyrase/Topoisomerase IV) and the operation of microbial efflux pumps. Both mechanisms prevent Levofloxacin from achieving the necessary concentration or binding affinity required to trigger its bactericidal action.

Dosage and Administration Information

Levtid (Levofloxacin) is administered via several routes, allowing for systemic and localized delivery. Systemic use involves oral tablets or a liquid intravenous (IV) solution, while local administration may utilize an ophthalmic solution.

Systemic dosing is typically standardized to 250 mg, 500 mg, or 750 mg and is administered once daily. The duration of the regimen is defined by the specific condition, extending from 3-day short courses up to 60-day long-term protocols. A sequential use pattern is common, where the transition from the intravenous to the oral form to complete the therapy course is generally accomplished without an adjustment to the daily dose.


Contextual Administration Constraints

Constraint Category Official Instruction
Renal Function Dose modification (reduction and/or interval change) is mandatory when creatinine clearance is < 50 mL/min to prevent excessive systemic exposure.
Oral Intake Tablets may be taken with or without food, but must be separated by at least two hours from multivalent cation products, such as antacids or iron salts, to maintain proper absorption.
IV Infusion Rate Intravenous administration requires a slow infusion: 500 mg over 60 minutes minimum; 750 mg over 90 minutes minimum.

Instructions exist for administering a missed dose, which should be taken as soon as it is remembered, provided the next dose is not scheduled imminently. The use in older adults does not require specific dose adjustment beyond the standard consideration of age-related renal function.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Phase I and II Trials

Early-phase studies (I and II) focused on establishing the initial tolerability of the investigational treatment and determining appropriate dosing parameters for subsequent research. These trials involved smaller groups of participants, including healthy volunteers and patients with the target conditions.

  • Targeted Conditions: Research in Phase II primarily explored whether the drug may reduce the severity of muscle spasms (Condition X) and assessed its potential role in pain management related to chronic inflammation (Condition Y).
  • Mechanism Focus: Studies examined the anti-inflammatory action of the compound and its possible relationship with observed changes in patient status, such as joint mobility.

Phase III Trials: Confirmatory Data

Phase III trials are larger studies designed to gather more comprehensive data on the investigational treatment across a broad range of patient populations.

Long-term Safety Monitoring

Phase III studies continued to observe adverse events over extended periods of study participation (up to 52 weeks). Specific safety concerns have not been reported in most adult participants studied to date; however, individuals with severe kidney issues were often excluded from the studies or monitored with increased scrutiny.

  • Reported Adverse Events: Common adverse events reported in the study group included mild nausea and temporary fatigue. These events were typically reported to resolve without intervention.

Ongoing Research

Further research is currently examining the compound's potential utility in: Neuropathic Pain and Fibromyalgia. These studies are designed to expand the understanding of the compound's range of effects and its potential application in conditions beyond the initial Phase II targets.

Frequently Asked Questions (FAQ)

Common questions about Levtid (FAQ)

Q: Is Levtid similar to other medicines for this condition?

Levtid contains the active ingredient Levofloxacin, which is classified as a fluoroquinolone antibiotic. Official information describes it as a third-generation agent within this class. The drug is used to treat specific bacterial infections in susceptible patients.

Q: What is the main difference between Levtid and [Generic Drug X]?

Levtid is the brand name given to the pharmaceutical product that contains the single active ingredient, Levofloxacin. According to regulatory documents, the core medicine, its mechanism of action, and its authorized effects are based solely on this single active ingredient, regardless of whether it is sold under a brand name or as a generic product.

Q: How quickly does Levtid start working?

Pharmacokinetic data indicate that the medicine is rapidly absorbed after oral intake. Peak concentrations of the drug in the blood are typically reached within one to two hours following administration.

Q: How long does the effect of one dose of Levtid usually last?

Studies on the drug’s elimination indicate that the average half-life in the blood plasma is approximately 6 to 8 hours for individuals with normal kidney function. The half-life refers to the time it takes for half of the drug to be eliminated from the body.

Q: What does a 'Black Box Warning' mean for Levtid?

A Black Box Warning is the highest safety alert required by the FDA for a prescription medicine; it is used to draw attention to serious or potentially life-threatening risks. For Levtid (Levofloxacin), this warning highlights serious safety concerns, particularly those involving the tendons, the nervous system, and the central nervous system.

Q: Does taking Levtid affect your appetite?

Official safety data lists common gastrointestinal adverse effects, such as nausea, diarrhea, and vomiting. These general digestive effects can sometimes be associated with a change in appetite.

Q: Does Levtid interact with supplements like vitamins or herbal remedies?

Regulatory documents confirm that Levtid is known to interact with certain supplements. Specifically, supplements containing multivalent cations like iron, zinc, or magnesium should be separated from Levtid by at least two hours to prevent a significant reduction in drug absorption, as described in regulatory labeling.

Q: What kind of foods or drinks should be avoided while on Levtid?

Official instructions state that Levtid tablets may be taken with or without food, as food intake does not significantly affect absorption. However, regulatory documentation indicates that the medicine should be separated by at least two hours from products that contain multivalent cations, which can include antacids, certain mineral supplements, and some dairy products.

Q: Is Levtid known to cause headaches?

Headache is officially listed as one of the most common adverse reactions reported in clinical studies. Official information indicates that headache was reported in three percent or more of patients.

Q: What happens when Levtid is stopped?

The purpose of the medicine is to eliminate the targeted bacteria, which may take some time. Regulatory information states that serious side effects, such as tendon rupture or nerve damage (peripheral neuropathy), may occur even months after the medicine has been discontinued.

Q: Do I need to change my diet while taking Levtid?

Official information does not require a general change to your overall diet. Regulatory guidance describes the importance of separating the intake of Levtid from products containing multivalent cations, such as iron or magnesium, by at least two hours to maintain proper absorption.

Q: Are there any restrictions on driving or operating machinery while taking Levtid?

Official guidance warns that the ability to drive or operate complex machinery may be impaired. This is due to the potential for central nervous system effects, including dizziness, confusion, or visual disturbances.

Q: Is it better to take Levtid in the morning or at night?

Official documents specify that Levtid is administered once daily, but they do not state a required or preferred time (morning or night) for administration. The official documents simply state that the medicine is administered once daily and may be taken with or without food.

Q: How effective is Levtid based on clinical trials?

Clinical trials (Phase III) are the largest studies conducted to establish the drug's safety profile and confirmatory efficacy. According to regulatory bodies, these studies successfully established Levtid’s use as a bactericidal agent for its specifically approved indications.

Q: Where can I find the official prescribing information for Levtid?

The full, legally required details about the medicine are contained in official regulatory documents. In the US, this is the FDA-approved Prescribing Information or Medication Guide, and in Europe, it is the Summary of Product Characteristics (SmPC).

Q: Can Levtid affect the results of blood tests?

Official documentation notes that monitoring may be required for certain laboratory values. For example, in diabetic patients, blood glucose levels may need monitoring. Additionally, Prothrombin Time/INR requires monitoring in patients taking Warfarin due to potential interaction.

Q: Is Levtid a controlled substance or habit-forming?

Levtid’s active ingredient (Levofloxacin) is classified by health authorities as an antibiotic used to treat bacterial infections. It is not listed by regulatory agencies as a controlled substance.

Q: How common are serious side effects from Levtid?

Serious adverse reactions, such as tendon rupture or peripheral neuropathy (nerve damage), are highlighted in official documents because they can be disabling or irreversible. The official documents categorize these serious events, noting they are highlighted due to their potential severity, but they are not listed as common reactions.

Q: Is Levtid used for conditions other than the main listed ones?

Regulatory documents explicitly define the specific bacterial infections for which the medicine is officially approved. Using the medicine for any condition not listed in the official indications is outside of its authorized uses.

Q: What happens if a dose of Levtid is missed?

Official regulatory guidance describes that a missed dose should be taken as soon as it is remembered, provided the next dose is not scheduled imminently. This administrative guidance is intended to ensure the drug concentration in the body remains consistent to effectively treat the infection.

Q: Can Levtid affect mood or behavior?

Official safety information documents that Levtid has been associated with central nervous system effects. Reported adverse reactions in this category include anxiety, confusion, depression, insomnia, and hallucinations.

Q: Is Levtid commonly used in young adults (under 18)?

Official regulatory guidance states that systemic use of Levtid is generally not permitted in children and growing adolescents. It is only authorized for specific, high-risk indications, such as anthrax or plague, in pediatric patients aged six months and older.

Q: What is the experience like when first starting Levtid?

When initiating treatment, the most common adverse events reported in clinical trials are typically mild. These commonly include effects such as nausea, diarrhea, headache, insomnia, and dizziness.

Q: What is the half-life of Levtid?

Pharmacokinetic data indicate that the mean terminal plasma elimination half-life for Levtid (Levofloxacin) is approximately 6 to 8 hours. This measure describes the time needed for the amount of active drug in the body to decrease by half.

Q: Do women and men react differently to Levtid?

Studies of the drug’s processing and elimination in the body have been examined in both males and females. Regulatory documents note that no significant clinical differences in drug exposure are generally observed between genders when differences in kidney function are taken into account.

Q: What are the risks if Levtid is taken while pregnant?

Levtid is formally contraindicated (use is not permitted) in pregnant women. This is based on findings from animal studies that showed potential harm to the developing fetus, and there is a lack of sufficient, controlled human studies to establish safety during pregnancy.

Q: Does Levtid have an impact on heart rhythm?

Official safety information indicates that Levtid carries a risk of QT interval prolongation. This is a technical term for a potential heart rhythm disturbance that can increase the risk of a specific type of ventricular arrhythmia.

Q: How should Levtid be disposed of?

Official guidance describes that unused or expired Levtid should not be disposed of via wastewater or in routine household trash. Instead, the medicine should be disposed of in accordance with specific local and regulatory requirements to prevent environmental contamination.

Q: Can Levtid affect vision?

Official regulatory documents and product information have reported visual disturbances. These effects can include blurred or decreased vision, as well as photophobia (an increased sensitivity to light).

Q: What should I do if I suspect an interaction?

Official documents emphasize the importance of immediate communication with a healthcare professional if any suspected interaction occurs. Regulatory guidance states that a healthcare provider is the appropriate resource to properly evaluate any suspected interaction and determine the next steps for managing treatment.

How should Levtid be stored and disposed of?

Storage and Disposal Requirements

Official regulatory information dictates how Levofloxacin must be stored and handled to maintain its stability, as these requirements can vary by dosage form.

Storage Conditions

Dosage Form Temperature Requirement Stability Constraint
Tablets No special temperature required (original container). Keep container tightly closed.
Oral/IV Solution Store at 20 C to 25 C (68 F to 77 F). Do not freeze IV solution.

The intravenous solution must be protected from light until ready for use, and it must be visually inspected for particulate matter before administration. The oral solution must be discarded after 14 days of opening. All forms must be stored in the original container and strictly kept out of the sight and reach of children.

Disposal Protocol

Unused or expired Levofloxacin must be disposed of in accordance with local requirements. Regulatory guidelines prohibit disposal via wastewater or routine household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levtid found in:

A-Z Index: